Clinical trial NCT05914844: Investigation Of Receptivity Markers For Endometrial Cancer Treatment Development
Official title: The Role Of Hyaluronan Receptor Cd44s And Has2 In Endometrial Malignities
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrial Cancer Stage
Keywords: endometrial carcinoma
immunohistochemistry
CD44s
HAS2
Lead sponsor: Celal Bayar University
Sponsor class: OTHER
First posted: 2023-06-22
Enrollment: 30
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with endometrium cancer

Brief summary: Hyaluronan is an extracellular matrix protein that is involved in cell-cell and cell-matrix interactions. Hyaluronan performs this activity through hyaladherins, which are intracellular and extracellular receptors.

The purpose of this study was to compare the distributions of Hyaluronan Synthetase 2 (HAS2) and CD44s in healthy endometrial tissue samples obtained during the proliferative phase endometrium (PPE) and secretory phase endometrium (SPE), as well as pathologic samples diagnosed with benign endometrial hyperplasia (EH), endometrial intraepithelial neoplasia (EIN), early stage of endometrial carcinoma (EC) (stage I/II) and advanced stage of endometrial carcinoma (stage III/IV) (n:5, each).

By using the avidin-biotin-peroxidase method, tissue samples that had been fixed with formalin passed through a regular paraffin follow-up protocol, and subsequently embedded in paraffin were stained indirectly with anti-CD44s and anti-HAS2 primary antibodies. Immunostaining intensity was graded as 0: negative, 1: weak, 2: moderate, 3: strong, and 4: very strong using a semiquantitative technique. The ANOVA test was used to assess the statistical significance of the findings. Statistical significance was defined as (p) values less than 0.05.

While weak HAS2 and weak/moderate CD44s immunoreactivity was observed on the surface epithelium (SE)/glandular epithelium (GE) and stroma of the tissue samples acquired during PPE; weak/moderate HAS2 and moderate CD44s immunoreactivity were observed in SPE and EH groups; moderate/strong HAS2, strong CD44s immunoreactivity was observed in EIN; strong/very strong HAS2 and very strong CD44s immunoreactivity were observed in early-stage EC and advanced stage EC. It was determined that the immunoreactivity intensity increased at a statistically significant level in both early and advanced stage EC.

The fact that HAS2 and CD44s, two intracellular receptors, have increased in endometrial carcinoma leads us to believe that they are likely to play a role in tumor development, invasion, migration, metastasis and that they may be useful in developing future treatment protocols targeting hyaluronan receptors.


Eligibility criteria: Inclusion Criteria:

- All patients with endometrial carcinoma underwent surgery.

Exclusion Criteria:

* No patient was subject to chemotherapy or radiotherapy prior to surgery.

Primary outcomes:
measure: Investigation Of Receptivity Markers For Endometrial Cancer Treatment Development
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Yunusemre
country: Turkey
facility: Manisa Celal Bayar University
state: Mani̇sa
Study officials:
References: